Bharat Biotech submitted data on COVID-19 drug trials in children

Bharat Biotech submitted data on COVID-19 drug trials in children. 

Bharat Biotech said on Wednesday it had submitted its data from the COVID-19 vaccine trial conducted in children. 

It ranges from 2 to 18 years to India’s drug regulator becoming the first Indian company to test its vaccine in infants and toddlers.

A South Asian country is turning its attention towards the vaccination of children against the coronavirus, having already administered over 920 million doses of vaccine to adults in the population of 1.4 billion.

India’s drug regulator in the last month granted the vaccine maker Serum Institute to enroll kids between 7 and 11 years old to test the U.S.

Pharmaceutical company Novavax’s (NVAX.O) COVID-19 vaccine.

Currently, only the drugmaker Zydus Cadila’s DNA-based COVID-19 vaccine has been approved for emergency use in India in children and adults aged between 12 years old.